Notably, extremely high hazard ratios were reported for mutations in the nuclear factor erythroid-2 (NFE2) gene, a hematopoietic transcription factor, for leukemic transformation or progression to MDS and OS (10.3 and 8.24, respectively; p < 0.001); and the rates of hematological response to treatment were significantly lower (p = 0.026) [68]. This evidence concerns the gene NFE2 and myelodysplastic syndrome.